Frail people may be more likely to have Aβ plaques and neurofibrillary tangles; when they do, they are more likely to have dementia. Physical activity correlated with better global cognition, regardless of brain pathology.
Reducing systolic blood pressure staves off cognitive decline, but what about dementia?
At AAIC, scientists said that alterations in how the aging female brain uses energy and metabolizes fat may leave APOE4 carriers particularly susceptible to tau pathology.
New work implicates changes in chromatin structure and failed DNA repair in neurodegeneration.
A longitudinal study finds that middle-aged people with the highest levels of inflammation markers in their blood succumb to the greatest cognitive decline over the next 20 years.
At a meeting in San Diego, researchers traded news about how TDP-43 gets trapped in the cytoplasm, finding both good and bad consequences of its exodus from the nucleus.
At an RNA metabolism meeting, scientists reported connections between C9ORF72 loss and gain of function. Their talks brimmed with new biology implicating autophagy, the cellular stress response, and RAN translation off introns.
Staufen1 may deplete certain mRNAs, precipitating the death of Purkinje and other neurons.
Using a new optogenetic model for TDP-43 phase transitions, scientists see the protein aggregate outside, not inside stress granules. The model distinguishes physiological from abnormal phase transition.
Deleting BACE1 with CRISPR nanocomplexes tempered Aβ pathology and boosted memory.
In Year Three, GAP Trial Network Is Starting to Hum Getting to Go: GAP-Net Sets Sight on Faster Start Three years after the Global Alzheimer’s Platform (GAP) Foundation launched GAP-Net, a standing network of clinical trial sites optimized for Alzheimer’s ...
From central IRBs, certified raters, to local transport: Changes large and small are needed to ramp up drug testing in Alzheimer’s.
Award recognizes his contributions to basic and clinical research.
With three trials and initiatives to boost recruitment, GAP-Net is gaining some traction in the field.
Experts said Phase 3 data did not prove the device could slow AD.